Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

The user is considering switching from topical finasteride to RU58841 or KX826 to reduce side effects but decides to stick with finasteride for now. Users discuss the effectiveness and risks of RU58841 and KX826, with finasteride being considered the most reliable option.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

A user seeks advice on mixing RU58841 serum using European ingredients, specifically struggling to find propylene glycol. They are looking for alternatives to American products commonly recommended in guides.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.

The conversation is about using a topical finasteride solution without minoxidil to avoid side effects, with suggestions to use alternatives like a PG solvent or Stemox. There is also a mention of mixing finasteride with fisetin powder in the solvent.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.

People are discussing experiences with finasteride for hair loss after being on testosterone for over two years. Users report varying results, with some experiencing regrowth and no side effects, while others emphasize the importance of starting treatment early to prevent further hair loss.

Pattern hair loss before age 35 may be linked to higher risks of prostate cancer, cardiovascular diseases, and metabolic syndrome later in life. Finasteride is discussed as a treatment that may lower PSA levels and potentially prevent prostate issues.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

RU58841 powder may degrade over time, even when stored in a freezer. Users discuss its potential effectiveness after three years of storage.

Concerns about France potentially banning finasteride and dutasteride due to supposed side effects, though no solid evidence supports this action. Users believe a ban is unlikely and discuss ways to obtain the treatments if it occurs.

Finasteride can increase testosterone levels and improve mood, with temporary side effects like brain fog that usually subside. The user reports positive results with finasteride, experiencing no hair loss and maintaining mental clarity after six months.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

The conversation is about using alfatradiol (17α-estradiol) as a hair loss treatment. The user is considering adding it to their regimen due to its safety and availability.

RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.

Being overweight may increase finasteride side effects due to higher aromatase activity converting testosterone to estradiol. Maintaining a healthy weight could reduce these side effects.

The conversation discusses the impact of finasteride on sperm, including potential side effects like decreased ejaculate volume and total sperm count. Users share experiences and concerns about fertility tests before and after starting finasteride.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

RU58841 shows the strongest results despite weaker binding affinity, while KX-826 and CB-03-01 are more expensive and have minimal side effects. RU58841 is considered effective but has potential health risks if ingested; users report positive outcomes with RU58841 and finasteride.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.